Neuren Pharmaceuticals: From New Zealand roots to ASX stardom

Neuren Pharmaceuticals: From New Zealand roots to ASX stardom
Neuren's Melbourne-based CEO Jon Pilcher credits the pharmaceutical firm's breakthrough medications to NZ research. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
It was the best-performing stock on the ASX in 2023, has a market cap of about $2.2 billion, doesn’t have an office, and was founded in New Zealand. Neuren Pharmaceutical’s medication trofinetide became the first US Food and Drug Administration (FDA) approved treatment for the disabling neurological disorder Rett syndrome in March 2023. Rett syndrome is rare, “profoundly debilitating”, and mostly affects female children. It leads to developmental delays and sometimes regressions as the child ages. Neuren s...

More Markets

Takeover bid is opportunistic and undervalued: THL
Markets

Takeover bid is opportunistic and undervalued: THL

Tourism Holdings' board remains open to engagement with the Consortium.

One man, five boards: The NZ director spiderweb
Markets

One man, five boards: The NZ director spiderweb

James Miller is at the top of the directorship pyramid.

Increased US tariffs drive NZ stocks lower
Markets Market Close

Increased US tariffs drive NZ stocks lower

F&P Healthcare and Ebos shares both dropped over 2% on the tariff news.

Jamie Gray 01 Aug 2025
Journee to succeed Withers as Warehouse chair
Retail

Journee to succeed Withers as Warehouse chair

Journee ensures "strong continuity of leadership", Joan Withers said.

Gregor Thompson 01 Aug 2025